MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

US$809,079K (3568.79%↑ Y/Y)Europe$119,010K (460.15%↑ Y/Y)Non USOr Europe$83,673K (805.65%↑ Y/Y)US$9,863K (-97.27%↓ Y/Y)Europe$5,508K (-94.07%↓ Y/Y)Non USOr Europe$3,090K (-91.81%↓ Y/Y)US$58,000K (5.17%↑ Y/Y)Europe$24,323K (16.01%↑ Y/Y)Non USOr Europe$7,441K (57.25%↑ Y/Y)Europe$22,678K (3.42%↑ Y/Y)US$18,545K (15.77%↑ Y/Y)Non USOr Europe$10,899K (22.13%↑ Y/Y)Amvuttra$1,011,762K (105.66%↑ Y/Y)ONPATTRO$18,461K (-64.86%↓ Y/Y)GIVLAARI$89,764K (11.03%↑ Y/Y)OXLUMO$52,122K (11.20%↑ Y/Y)TTR$1,030,223K (89.21%↑ Y/Y)Rare$141,886K (11.09%↑ Y/Y)Roche$41,888K (129.31%↑ Y/Y)RegeneronPharmaceuticals Incorporation$5,020K (-84.57%↓ Y/Y)Other Collaborations$257K (-97.60%↓ Y/Y)Product$1,172,109K (74.37%↑ Y/Y)Royalty$71,674K (79.27%↑ Y/Y)Collaborations$47,165K (-23.30%↓ Y/Y)Total revenues$1,290,948K (66.86%↑ Y/Y)Income (loss) fromoperations$231,441K (1528.74%↑ Y/Y)Total operating costsand expenses$1,059,507K (34.13%↑ Y/Y)Income (loss) beforeincome taxes$177,806K (602.87%↑ Y/Y)Total other expense,net-$53,635K (-179.95%↓ Y/Y)Interest income$28,143K (2.39%↑ Y/Y)Other income(expense), net$273K (104.27%↑ Y/Y)Research and development$413,134K (27.66%↑ Y/Y)Selling, general andadministrative$347,922K (7.61%↑ Y/Y)Cost of goods sold$298,261K (110.00%↑ Y/Y)Cost ofcollaborations and royalties$190K (-79.44%↓ Y/Y)Net income (loss)$164,494K (348.19%↑ Y/Y)Provision for income taxes$13,312K (-56.95%↓ Y/Y)Interest expense$82,051K (103.87%↑ Y/Y)Comprehensive income (loss)$157,250K (367.83%↑ Y/Y)Total othercomprehensive (gain) income-$7,244K (-195.76%↓ Y/Y)Defined benefit pensionplans, net of tax-$89K (-67.92%↓ Y/Y)Foreign currencytranslation (gaines) losss-$3,698K (-147.08%↓ Y/Y)Unrealized (gaines) lossson marketable...-$3,635K (-959.77%↓ Y/Y)
Income Statement
logo (21)-svg-svg

ALNYLAM PHARMACEUTICALS, INC. (ALNY)

logo (21)-svg-svg

ALNYLAM PHARMACEUTICALS, INC. (ALNY)

source: myfinsight.com